viernes, 20 de noviembre de 2026
Small Innovators, Big Hurdles: How Company Size Affects De Novo Success November 20, 2026 By Jennifer D. Newberger —
https://www.thefdalawblog.com/2026/11/small-innovators-big-hurdles-how-company-size-affects-de-novo-success/?utm_source=rss&utm_medium=rss&utm_campaign=small-innovators-big-hurdles-how-company-size-affects-de-novo-success
At the MedTech conference in Boston in October, CDRH shared a finding that deserves more attention than the overall de novo grant rate: small businesses (defined as those that received a Small Business Determination from FDA, which, for reduced de novo application fees, includes companies with gross receipts or sales of no more than $100 million for the most recent tax year) had less success than their “large” counterparts. CDRH reported an overall granting rate of approximately 45–55% from year to year, but the aggregate rate obscures the company-size divide. The slide does not quantify that gap or explain its causes, so it cannot establish why smaller companies fare worse. It does, however, raise a central question: is the pathway equally navigable for small innovators and larger, better-resourced companies? Several of CDRH’s observations suggest where the practical imbalance may arise:
Suscribirse a:
Enviar comentarios (Atom)


No hay comentarios:
Publicar un comentario